title: Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.forename: Van
authors.initials: V
authors.lastname: Morris
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Cameron C
authors.initials: CC
authors.lastname: Yin
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Burton
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl